<DOC>
	<DOC>NCT02764554</DOC>
	<brief_summary>The purpose of this post-marketing surveillance (PMS) is to observe the safety profile of Lenvima (lenvatinib) in normal clinical practice setting.</brief_summary>
	<brief_title>Post-Marketing Surveillance of Lenvima in Korean Patients</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Lenvatinib</mesh_term>
	<criteria>Inclusion criteria: Participants who meet the following criteria will be eligible for inclusion in the study: 1. Participants with approved indication for lenvatinib in Korea 2. Participants who have written consent for use of personal and medical information for the study purpose Investigators will refer to approved indications and contraindications regarding exclusion criteria</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Post-Marketing Surveillance</keyword>
	<keyword>Lenvima</keyword>
	<keyword>Lenvatinib</keyword>
	<keyword>E7080</keyword>
	<keyword>Differentiated thyroid carcinoma</keyword>
	<keyword>Refractory to radioactive iodine</keyword>
	<keyword>Progressive</keyword>
	<keyword>locally recurrent</keyword>
	<keyword>metastatic</keyword>
</DOC>